EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1

Lu Xiao, Lu Li, Shasha Wu, Zhaoyi Che, Yuyang Du, Jingyi Zheng, Jingsong Yan, Hao Wang, Hong Zhang, Yan Li, Jia Xiao

eLife · 28.07.2026 · 15

DOI: 10.7554/elife.109174.4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 28.07.2026. Verfasst von Lu Xiao und 10 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Projects in Guangzhou, The Sixth Affiliated Hospital of Jinan University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While magnesium isoglycyrrhizinate (MgIG) is a clinically approved therapy for alcohol-associated liver disease (ALD), its precise molecular targets and mechanisms remain uncharacterized. This study aimed to define MgIG’s hepatoprotective actions in chronic-binge ALD mouse models and ethanol/palmitic acid-exposed AML-12 hepatocytes. Through an integrated strategy encompassing RNA sequencing, molecular docking, and microscale thermophoresis, we discovered that MgIG directly binds to hydroxysteroid 11-beta dehydrogenase 1 (HSD11B1) at residue 187, a finding corroborated by molecular dynamics simulations. In vivo, MgIG markedly attenuated alcohol-induced liver injury, evidenced by ameliorated histological damage, reduced hepatic steatosis, and normalized liver-to-body weight ratios. In vitro, it effectively reduced lipid accumulation, inflammation, and apoptosis. Mechanistically, RNA sequencing identified isopentenyl diphosphate delta isomerase 1 (IDI1) as a key downstream effector. Hepatocyte-specific genetic manipulations confirmed that MgIG modulates the SREBP2–IDI1 axis, thereby suppressing lipogenesis, inflammatory responses, and apoptotic pathways. We reveal HSD11B1 as a novel direct molecular target of MgIG and elucidate its therapeutic mechanism through the HSD11B1–SREBP2–IDI1 signaling axis, which profoundly impacts ALD pathogenesis. These findings not only validate MgIG’s clinical utility but also highlight a promising new therapeutic target for ALD.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Projects in Guangzhou
  • The Sixth Affiliated Hospital of Jinan University

Zitieren

APA

Xiao, L., Li, L., Wu, S., Che, Z., Du, Y., Zheng, J., Yan, J., Wang, H., Zhang, H., Li, Y., & Xiao, J. (2026). Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1. eLife, 15. https://doi.org/10.7554/elife.109174.4

Vancouver

Xiao L, Li L, Wu S, Che Z, Du Y, Zheng J, et al. Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1. eLife. 2026;15. doi:10.7554/elife.109174.4

BibTeX
@article{Xiao2026,
  author = {Xiao, Lu and Li, Lu and Wu, Shasha and Che, Zhaoyi and Du, Yuyang and Zheng, Jingyi and Yan, Jingsong and Wang, Hao and Zhang, Hong and Li, Yan and Xiao, Jia},
  title = {Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1},
  journal = {eLife},
  year = {2026},
  volume = {15},
  doi = {10.7554/elife.109174.4}
}
Kostenlos starten →